Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial

The Breast · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles